Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability.
Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B, Li J, Kelly V, Saltz L, Mandelker D, Ladanyi M, Berger M, Klimstra D, Reidy-Lagunes D, Osoba M. Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. JCO Precision Oncology 2018, 2018: 1-18. PMID: 30687805, PMCID: PMC6345401, DOI: 10.1200/po.17.00267.Peer-Reviewed Original ResearchMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer TargetsNext-generation sequencingPancreatic neuroendocrine tumorsGermline genetic analysisLoss of heterozygosityMetastatic PanNETsNeuroendocrine tumorsHigh-penetrance cancer susceptibility genesPresence of loss of heterozygosityAdvanced pancreatic neuroendocrine tumorsMetastatic pancreatic neuroendocrine tumorsGenetic analysisSomatic loss of heterozygosityInferior overall survivalCancer susceptibility genesIncreasing tumor gradeTarget of rapamycin pathway genesRoutine clinical practice settingClonal evolution patternsMammalian target of rapamycin pathway genesChromatin remodeling factorsReal-time molecular profilingFrequent somatic mutationsClinical practice settingSequence of pre-
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply